[article]
| Titre : |
Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur |
| Article en page(s) : |
p.1773-1783 |
| Langues : |
Anglais (eng) |
| Mots-clés : |
Autistic disorder Double-blind Placebo-controlled Risperidone |
| Index. décimale : |
PER Périodiques |
| Résumé : |
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(?12.4 [6.5]; p 0.001), but not low-dose (?7.4 [8.1]; p = 0.164) group, versus placebo (?3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. |
| En ligne : |
http://dx.doi.org/10.1007/s10803-012-1723-5 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205 |
in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783
[article] Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study [Texte imprimé et/ou numérique] / Justine M. KENT, Auteur ; Stuart KUSHNER, Auteur ; Xiaoping NING, Auteur ; Keith KARCHER, Auteur ; Seth NESS, Auteur ; Michael G. AMAN, Auteur ; Jaskaran SINGH, Auteur ; David HOUGH, Auteur . - p.1773-1783. Langues : Anglais ( eng) in Journal of Autism and Developmental Disorders > 43-8 (August 2013) . - p.1773-1783
| Mots-clés : |
Autistic disorder Double-blind Placebo-controlled Risperidone |
| Index. décimale : |
PER Périodiques |
| Résumé : |
Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5–17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg], 0.175 mg/day [45 kg] or high-dose: 1.25 mg/day [20 to 45 kg], 1.75 mg/day [45 kg]) or placebo. Mean baseline (range 27–29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose—(?12.4 [6.5]; p 0.001), but not low-dose (?7.4 [8.1]; p = 0.164) group, versus placebo (?3.5 [10.7]). Clinical Global Impressions-Severity and Children’s Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently. |
| En ligne : |
http://dx.doi.org/10.1007/s10803-012-1723-5 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=205 |
|
Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study in Journal of Autism and Developmental Disorders, 43-8 (August 2013)
